Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 848 across all filing types
Latest filing 2018-10-11 Director's Dealing
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-10-11 English
FORM 4 SUBMISSION
Director's Dealing
2018-10-11 English
FORM 4 SUBMISSION
Director's Dealing
2018-10-11 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-10-10 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 5, 2018, reporting the entry into a material definitive underwriting agreement related to a public offering of common stock and warrants. It details the terms of the offering, the use of proceeds, and includes exhibits such as the underwriting agreement and legal opinion. The content focuses on a financing event and capital raising activity. There are no financial statements or earnings data presented, nor is it an announcement of voting results, management changes, or legal proceedings. The primary subject is the company's capital raising through a public offering, which fits the Capital/Financing Update category.
2018-10-05 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock and warrants. It includes detailed information about the offering terms, risk factors, use of proceeds, underwriting, and legal matters. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other type of report. It is clearly an update on financing activities and capital structure changes related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2018-10-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.